Idiopathic Interstitial Pneumonias

This is a group of lung diseases where the tissue between the air sacs gets damaged, but the cause is unknown. It's not caused by things like cirrhosis or parasitic infections. There are different types, and they can be serious.

Condition

What people with Idiopathic Interstitial Pneumonias report

Every report comes from a Lived member, sent anonymously.

Have you tried Home oxygen therapy for Idiopathic Interstitial Pneumonias?

NameHow it went

About Idiopathic Interstitial Pneumonias

What It Is

Idiopathic interstitial pneumonias (IIPs) are a group of lung diseases in which the tissue around the tiny air sacs becomes inflamed, scarred, or both, without an identifiable cause. "Idiopathic" means the cause is unknown, and "interstitial" refers to the thin supporting tissue between the air sacs, where oxygen passes into the blood. When that tissue thickens or stiffens, the lungs take in oxygen less efficiently. The result is usually shortness of breath on exertion and a persistent dry cough, often developing gradually. IIP is an umbrella term rather than a single disease. Idiopathic pulmonary fibrosis (IPF), a steadily scarring form, is by far the most common. Others include nonspecific interstitial pneumonia, cryptogenic organizing pneumonia, two smoking-related forms (desquamative interstitial pneumonia and respiratory bronchiolitis-associated interstitial lung disease), the sudden and severe acute interstitial pneumonia, and a few rare types. The distinction matters because the subtypes behave very differently: some respond well to treatment and others progress despite it.

Causes & Risk Factors

By definition, no specific cause is found. Doctors reach this label only after ruling out known causes of lung scarring, such as autoimmune diseases like rheumatoid arthritis, reactions to inhaled molds or bird proteins, workplace dusts such as asbestos or silica, and certain medicines. Some risk factors are well established, even though they do not explain any one person's illness. Smoking is strongly linked to several subtypes; desquamative interstitial pneumonia and respiratory bronchiolitis-associated disease occur almost entirely in people who smoke or used to. IPF is more common with older age (usually after 50 and most often in the 60s and 70s), in men, and in people with a parent or sibling who has pulmonary fibrosis. Changes in more than 10 genes have been linked to a higher risk of IPF. Nonspecific interstitial pneumonia, by contrast, more often affects women in middle age who have never smoked.

How It's Diagnosed

Because the symptoms are common to many lung and heart problems, diagnosis starts with a detailed history: how long symptoms have lasted, smoking, medicines, family history of lung scarring, signs of autoimmune disease, and exposures at home and work over many years. On examination, a doctor may hear fine crackling sounds at the base of the lungs or notice clubbing, a rounding and widening of the fingertips. High-resolution computed tomography (CT), a detailed chest scan, is the most useful single test. The pattern and location of changes on the scan often point to a particular subtype, and in typical IPF the scan alone may be enough. Breathing tests (pulmonary function tests) measure how much air the lungs hold and how well oxygen crosses into the blood; they show severity and are repeated to track change over time, but they cannot tell the subtypes apart. Blood tests look for autoimmune diseases that can cause the same picture. When the history and scan do not settle the question, a lung biopsy may be needed. Options include a cryobiopsy taken through a flexible tube passed into the airways, or a small keyhole surgical biopsy, which provides the most tissue. Biopsy carries risks such as bleeding or a collapsed lung, so the decision is weighed case by case. Because no single test is decisive, the diagnosis is ideally made by a lung specialist, a radiologist and a pathologist reviewing the findings together. Some cases still cannot be placed in one category and are called unclassifiable.

Treatment Options

Treatment depends on the subtype, which is one reason an accurate diagnosis matters. For IPF, the main treatments are antifibrotic medicines, which slow the scarring process. Nintedanib (Ofev) and pirfenidone (Esbriet, also available as a generic) slow the loss of lung function over time; they do not reverse existing scarring or restore breathing capacity, so the benefit is measured as decline that is slower than it would otherwise be. Nerandomilast (Jascayd), a newer medicine of a different type, was approved in 2025 for IPF and for progressive scarring in other lung diseases. Common side effects of antifibrotics include diarrhea, nausea and reduced appetite, and pirfenidone can cause rashes with sun exposure. Regular blood tests check for liver effects. Steroids are not used to treat stable IPF because they do not help it. For nonspecific interstitial pneumonia, cryptogenic organizing pneumonia and lymphoid interstitial pneumonia, which involve more inflammation, corticosteroids such as prednisone are the usual starting treatment. Other immune-suppressing medicines, such as mycophenolate or azathioprine, may be added or used to reduce steroid doses. When one of these forms keeps scarring despite treatment, an antifibrotic may also be considered. Stopping smoking helps in every subtype and is the core treatment for the two smoking-related forms, which often improve substantially once smoking stops. Supportive care matters across the group: supplemental oxygen eases breathlessness and helps people stay active, and pulmonary rehabilitation (a supervised program of exercise, breathing techniques and education) improves stamina and quality of life. For people with advanced disease who are otherwise healthy enough, a lung transplant may be an option; it requires lifelong anti-rejection medicines.

What to Expect

The outlook varies more by subtype than almost any other factor. Cryptogenic organizing pneumonia usually responds well to steroids, and long-term survival is high. Nonspecific interstitial pneumonia generally has a better course than IPF, particularly when inflammation rather than scarring predominates. The smoking-related forms often stabilize or improve after quitting. IPF is a long-term, progressive disease with no cure, and its pace is hard to predict. Some people stay stable for years while others decline more quickly. Breathlessness tends to extend gradually from exertion to everyday tasks, and some people eventually need oxygen at home or when out. Acute interstitial pneumonia is different again: it develops over days to weeks, often requires intensive care, and is frequently fatal, although some people recover. Follow-up usually means breathing tests every few months, periodic CT scans and, for people on antifibrotics, blood tests. Living with a progressive lung disease can bring anxiety, depression and sleep problems, and complications of IPF can include lung cancer and high blood pressure in the lungs (pulmonary hypertension). Pulmonary rehabilitation, support groups and palliative care (care focused on comfort and quality of life, which can run alongside other treatment) help many people and families manage the practical and emotional load. Early conversations about transplant eligibility and future care preferences make later decisions easier.

When to Seek Help

See a doctor if you have breathlessness with activity or a dry cough that has lasted more than a few weeks without an obvious cause, especially if you have a family history of pulmonary fibrosis. If you already have a diagnosis, bring up new side effects from medicines or a gradual change in how far you can walk. Contact your care team promptly if your breathing gets noticeably worse over days or weeks, if you become short of breath at rest or with very slight activity, or if you develop a fever with worsening cough. A rapid worsening can be an acute exacerbation, a serious flare that needs quick assessment. Call 911 if breathing difficulty comes on suddenly or becomes so severe that it is hard to speak.

Questions to Ask Your Doctor

  1. 1.Which subtype do I have, and how confident are we in that diagnosis without, or with, a biopsy?
  2. 2.Is my disease mainly inflammation, mainly scarring, or both, and what does that mean for which treatments are likely to help?
  3. 3.How will we measure whether my condition is stable or progressing, and how often will I need breathing tests and scans?
  4. 4.Would pulmonary rehabilitation or oxygen help me now, including during exercise or travel?
  5. 5.At what point should we talk about lung transplant evaluation or palliative care, and what would those involve?

Last reviewed • Oct 2026

Educational content, not medical advice.